Silymarin Improved 6-OHDA-induced Motor Impairment in Hemi-parkisonian Rats: Behavioral and Molecular Study

Overview

Journal Daru

Specialty Pharmacology

Date 2014 Apr 15

PMID 24726284

Citations 12

Authors

Rasool Haddadi

Alireza Mohajjel Nayebi

Safar Farajniya

Shahla Eyvari Brooshghalan

Hamdolah Sharifi

Affiliations

Soon will be listed here.

Abstract

Background: Neuroinflammation and oxidative stress has been shown to be associated with the development of Parkinson disease (PD). In the present study, we investigated the effect of intraperitoneal (i.p.) administration of silymarin, on 6-OHDA-induced motor-impairment, brain lipid per-oxidation and cerebrospinal fluid (CSF) levels of inflammatory cytokine in the rats.

Results: The results showed that silymarin is able to improve motor coordination significantly (p < 0.001) in a dose dependent manner. There was a significant (p < 0.001) increase in MDA levels of 6-OHDA-lesioned rats whereas; in silymarin (100, 200 and 300 mg/kg, i.p. for 5 days) pre-treated hemi-parkinsonian rats MDA levels was decreased markedly (p < 0.001). Furthermore the CSF levels of IL-1β was decreased (p < 0.001) in silymarin (100, 200 and 300 mg/kg) pre-treated rats up to the range of normal non-parkinsonian animals.

Conclusion: We found that pre-treatment with silymarin could improve 6-OHDA-induced motor imbalance by attenuating brain lipid per-oxidation as well as CSF level of IL-1β as a pro-inflammatory cytokine. We suggest a potential prophylactic effect for silymarin in PD. However, further clinical trial studies should be carried out to prove this hypothesis.

Citing Articles

Auricular acupuncture plays a neuroprotective role in 6-hydroxydopamine-induced Parkinson's disease in rats.

Nguyen H, Lee D, Hsieh C J Tradit Complement Med. 2025; 15(2):128-139.

PMID: 40060148 PMC: 11883624. DOI: 10.1016/j.jtcme.2024.05.008.

Behavioral analysis of motor and non-motor impairment in rodent models of Parkinson's disease.

Sheta R, Berard M, Musiol D, Martinez-Drudis L, Oueslati A Front Aging Neurosci. 2025; 16:1464706.

PMID: 39763579 PMC: 11701160. DOI: 10.3389/fnagi.2024.1464706.

Mechanistic Insights into the Pharmacological Significance of Silymarin.

Wadhwa K, Pahwa R, Kumar M, Kumar S, Chander Sharma P, Singh G Molecules. 2022; 27(16).

PMID: 36014565 PMC: 9414257. DOI: 10.3390/molecules27165327.

An Overview of Crucial Dietary Substances and Their Modes of Action for Prevention of Neurodegenerative Diseases.

Pogacnik L, Ota A, Poklar Ulrih N Cells. 2020; 9(3).

PMID: 32121302 PMC: 7140513. DOI: 10.3390/cells9030576.

Silymarin Protects Against Impaired Autophagy Associated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Induced Parkinsonism.

Tripathi M, Rasheed M, Mishra A, Patel D, Singh M J Mol Neurosci. 2019; 70(2):276-283.

PMID: 31732923 DOI: 10.1007/s12031-019-01431-8.

References

Manna S, Mukhopadhyay A, Van N, Aggarwal B . Silymarin suppresses TNF-induced activation of NF-kappa B, c-Jun N-terminal kinase, and apoptosis. J Immunol. 1999; 163(12):6800-9. View

Hirsch E, Hunot S . Neuroinflammation in Parkinson's disease: a target for neuroprotection?. Lancet Neurol. 2009; 8(4):382-97. DOI: 10.1016/S1474-4422(09)70062-6. View

Block M, Hong J . Chronic microglial activation and progressive dopaminergic neurotoxicity. Biochem Soc Trans. 2007; 35(Pt 5):1127-32. DOI: 10.1042/BST0351127. View

Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T . Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett. 1994; 165(1-2):208-10. DOI: 10.1016/0304-3940(94)90746-3. View

Wang M, Lin W, Chen H, Chang Y, Ou H, Kuo J . Silymarin protects dopaminergic neurons against lipopolysaccharide-induced neurotoxicity by inhibiting microglia activation. Eur J Neurosci. 2002; 16(11):2103-12. DOI: 10.1046/j.1460-9568.2002.02290.x. View

Floyd R . Antioxidants, oxidative stress, and degenerative neurological disorders. Proc Soc Exp Biol Med. 1999; 222(3):236-45. DOI: 10.1046/j.1525-1373.1999.d01-140.x. View

Shadrina M, Slominsky P, Limborska S . Molecular mechanisms of pathogenesis of Parkinson's disease. Int Rev Cell Mol Biol. 2010; 281:229-66. DOI: 10.1016/S1937-6448(10)81006-8. View

Morroni F, Tarozzi A, Sita G, Bolondi C, Zolezzi Moraga J, Cantelli-Forti G . Neuroprotective effect of sulforaphane in 6-hydroxydopamine-lesioned mouse model of Parkinson's disease. Neurotoxicology. 2013; 36:63-71. DOI: 10.1016/j.neuro.2013.03.004. View

Cicchetti F, Brownell A, Williams K, Chen Y, Livni E, Isacson O . Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. Eur J Neurosci. 2002; 15(6):991-8. DOI: 10.1046/j.1460-9568.2002.01938.x. View

10.

Varcin M, Bentea E, Michotte Y, Sarre S . Oxidative stress in genetic mouse models of Parkinson's disease. Oxid Med Cell Longev. 2012; 2012:624925. PMC: 3399377. DOI: 10.1155/2012/624925. View

11.

Rodriguez-Oroz M, Jahanshahi M, Krack P, Litvan I, Macias R, Bezard E . Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms. Lancet Neurol. 2009; 8(12):1128-39. DOI: 10.1016/S1474-4422(09)70293-5. View

12.

Mogi M, Harada M, Kondo T, Riederer P, Inagaki H, Minami M . Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci Lett. 1994; 180(2):147-50. DOI: 10.1016/0304-3940(94)90508-8. View

13.

Nagatsu T, Mogi M, Ichinose H, Togari A . Changes in cytokines and neurotrophins in Parkinson's disease. J Neural Transm Suppl. 2001; (60):277-90. DOI: 10.1007/978-3-7091-6301-6_19. View

14.

Gupta O, Sing S, Bani S, Sharma N, Malhotra S, Gupta B . Anti-inflammatory and anti-arthritic activities of silymarin acting through inhibition of 5-lipoxygenase. Phytomedicine. 2000; 7(1):21-4. DOI: 10.1016/S0944-7113(00)80017-3. View

15.

Yaghmaei P, Azarfar K, Dezfulian M, Ebrahim-Habibi A . Silymarin effect on amyloid-β plaque accumulation and gene expression of APP in an Alzheimer's disease rat model. Daru. 2014; 22(1):24. PMC: 3904165. DOI: 10.1186/2008-2231-22-24. View

16.

Lee J, Tran T, Tansey M . Neuroinflammation in Parkinson's disease. J Neuroimmune Pharmacol. 2009; 4(4):419-29. PMC: 3736976. DOI: 10.1007/s11481-009-9176-0. View

17.

Brodacki B, Staszewski J, Toczylowska B, Kozlowska E, Drela N, Chalimoniuk M . Serum interleukin (IL-2, IL-10, IL-6, IL-4), TNFalpha, and INFgamma concentrations are elevated in patients with atypical and idiopathic parkinsonism. Neurosci Lett. 2008; 441(2):158-62. DOI: 10.1016/j.neulet.2008.06.040. View

18.

Muzes G, Deak G, Lang I, Nekam K, Gergely P, Feher J . Effect of the bioflavonoid silymarin on the in vitro activity and expression of superoxide dismutase (SOD) enzyme. Acta Physiol Hung. 1991; 78(1):3-9. View

19.

Mandegary A, Saeedi A, Eftekhari A, Montazeri V, Sharif E . Hepatoprotective effect of silyamarin in individuals chronically exposed to hydrogen sulfide; modulating influence of TNF-α cytokine genetic polymorphism. Daru. 2013; 21(1):28. PMC: 3626872. DOI: 10.1186/2008-2231-21-28. View

20.

Qin L, Wu X, Block M, Liu Y, Breese G, Hong J . Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia. 2007; 55(5):453-62. PMC: 2871685. DOI: 10.1002/glia.20467. View